323 related articles for article (PubMed ID: 29927572)
1. Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.
Raab M; Sanhaji M; Pietsch L; Béquignon I; Herbrand AK; Süß E; Gande SL; Caspar B; Kudlinzki D; Saxena K; Sreeramulu S; Schwalbe H; Strebhardt K; Biondi RM
ACS Chem Biol; 2018 Aug; 13(8):1921-1931. PubMed ID: 29927572
[TBL] [Abstract][Full Text] [Related]
2. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
[TBL] [Abstract][Full Text] [Related]
4. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors.
Lin TY; Min HP; Jiang C; Niu MM; Yan F; Xu LL; Di B
Bioorg Med Chem; 2018 Jul; 26(12):3429-3437. PubMed ID: 29807699
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1.
Li Z; Zhang Z; Chen Y; Tang S; Lin T; Huang J; Li B; Jiang C
Bioorg Chem; 2019 Apr; 85():534-540. PubMed ID: 30807896
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
Berg A; Berg T
Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
[TBL] [Abstract][Full Text] [Related]
9. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X
Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998
[TBL] [Abstract][Full Text] [Related]
10. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
Chapagai D; Ramamoorthy G; Varghese J; Nurmemmedov E; McInnes C; Wyatt MD
J Med Chem; 2021 Jul; 64(14):9916-9925. PubMed ID: 34210138
[TBL] [Abstract][Full Text] [Related]
11. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.
Murugan RN; Park JE; Kim EH; Shin SY; Cheong C; Lee KS; Bang JK
Mol Cells; 2011 Sep; 32(3):209-20. PubMed ID: 21809214
[TBL] [Abstract][Full Text] [Related]
12. Pinning down the polo-box domain.
Lee KS; Idle JR
Chem Biol; 2008 May; 15(5):415-6. PubMed ID: 18482691
[TBL] [Abstract][Full Text] [Related]
13. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors.
Yun T; Qin T; Liu Y; Lai L
Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392
[TBL] [Abstract][Full Text] [Related]
14. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.
Yuan J; Sanhaji M; Krämer A; Reindl W; Hofmann M; Kreis NN; Zimmer B; Berg T; Strebhardt K
Am J Pathol; 2011 Oct; 179(4):2091-9. PubMed ID: 21839059
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
[TBL] [Abstract][Full Text] [Related]
16. Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting.
Hanisch A; Wehner A; Nigg EA; Silljé HH
Mol Biol Cell; 2006 Jan; 17(1):448-59. PubMed ID: 16267267
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
[TBL] [Abstract][Full Text] [Related]
18. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
Zhao XZ; Hymel D; Burke TR
Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
[TBL] [Abstract][Full Text] [Related]
19. Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1.
Richter S; Neundorf I; Loebner K; Gräber M; Berg T; Bergmann R; Steinbach J; Pietzsch J; Wuest F
Bioorg Med Chem Lett; 2011 Aug; 21(16):4686-9. PubMed ID: 21778054
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
Yan F; Liu G; Chen T; Fu X; Niu MM
Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
